1. Home
  2. GXAI vs APVO Comparison

GXAI vs APVO Comparison

Compare GXAI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GXAI
  • APVO
  • Stock Information
  • Founded
  • GXAI 2021
  • APVO 2016
  • Country
  • GXAI United States
  • APVO United States
  • Employees
  • GXAI 3
  • APVO N/A
  • Industry
  • GXAI
  • APVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GXAI
  • APVO Health Care
  • Exchange
  • GXAI Nasdaq
  • APVO Nasdaq
  • Market Cap
  • GXAI 11.3M
  • APVO 5.4M
  • IPO Year
  • GXAI 2023
  • APVO N/A
  • Fundamental
  • Price
  • GXAI $1.63
  • APVO $3.51
  • Analyst Decision
  • GXAI
  • APVO Strong Buy
  • Analyst Count
  • GXAI 0
  • APVO 1
  • Target Price
  • GXAI N/A
  • APVO $296.00
  • AVG Volume (30 Days)
  • GXAI 611.9K
  • APVO 45.8K
  • Earning Date
  • GXAI 03-26-2025
  • APVO 03-04-2025
  • Dividend Yield
  • GXAI N/A
  • APVO N/A
  • EPS Growth
  • GXAI N/A
  • APVO N/A
  • EPS
  • GXAI N/A
  • APVO N/A
  • Revenue
  • GXAI $2,979.00
  • APVO N/A
  • Revenue This Year
  • GXAI N/A
  • APVO N/A
  • Revenue Next Year
  • GXAI N/A
  • APVO N/A
  • P/E Ratio
  • GXAI N/A
  • APVO N/A
  • Revenue Growth
  • GXAI N/A
  • APVO N/A
  • 52 Week Low
  • GXAI $1.01
  • APVO $3.01
  • 52 Week High
  • GXAI $16.27
  • APVO $399.60
  • Technical
  • Relative Strength Index (RSI)
  • GXAI 45.49
  • APVO 33.23
  • Support Level
  • GXAI $1.41
  • APVO $3.01
  • Resistance Level
  • GXAI $2.00
  • APVO $3.96
  • Average True Range (ATR)
  • GXAI 0.17
  • APVO 0.32
  • MACD
  • GXAI 0.04
  • APVO -0.00
  • Stochastic Oscillator
  • GXAI 43.08
  • APVO 30.77

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: